Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin


Por: Van Den Hoek A.M., Voshol P.J., Karnekamp B.N., Buijs R.M., Romijn J.A., Havekes L.M., Pijl H.

Publicada: 1 ene 2004
Resumen:
Recent evidence demonstrates that hypothalamic insulin signaling is required for inhibition of endogenous glucose production. The downstream mechanisms that are responsible for the effects of hypothalamic insulin receptor activation on hepatic fuel flux remain to be determined. To establish whether downregulation of neuropeptide Y (NPY) release by insulin is mandatory for its capacity to suppress glucose production, we examined the effects of a continuous intracerebroventricular (ICV) infusion of NPY (10 ?g/h for 3-5 h) on glucose flux during a hyperinsulinemic-euglycemic clamp in mice. We also evaluated the effects of ICV NPY administration on free fatty acid and glycerol flux and VLDL production in this experimental context. In basal conditions, none of the metabolic parameters was affected by NPY infusion. In hyperinsulinemic conditions, peripheral glucose disposal was not different between vehicle- and NPY-infused animals. In contrast, hyperinsulinemia suppressed endogenous glucose production by ?8% vs. 30% in NPY- vs. vehicle-infused mice, respectively (P < 0.05). Also, VLDL production was significantly higher during hyperinsulinemia in NPY-compared with vehicle-infused mice (97.5 ± 18.0 vs. 54.7 ± 14.9 ?mol · kg-1 · h-1; P < 0.01). These data suggest that the neurophysiological action of insulin to downregulate hypothalamic NPY release is a prerequisite for its ability to suppress hepatic fuel production, whereas it is not mandatory for its capacity to modulate glucose disposal or lipolysis.

Filiaciones:
Van Den Hoek A.M.:
 Org. of Appl. Sci. Res.-Prev./Hlth., Gaubius Laboratory, Leiden, Netherlands

 Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands

Voshol P.J.:
 Org. of Appl. Sci. Res.-Prev./Hlth., Gaubius Laboratory, Leiden, Netherlands

 Dept. of Endocrinol. and Metab. Dis., Leiden University Medical Center, Leiden, Netherlands

Karnekamp B.N.:
 Org. of Appl. Sci. Res.-Prev./Hlth., Gaubius Laboratory, Leiden, Netherlands

Buijs R.M.:
 Netherlands Inst. for Brain Research, Amsterdam, Netherlands

Romijn J.A.:
 Dept. of Endocrinol. and Metab. Dis., Leiden University Medical Center, Leiden, Netherlands

Havekes L.M.:
 Org. of Appl. Sci. Res.-Prev./Hlth., Gaubius Laboratory, Leiden, Netherlands

 Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands

 Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands

Pijl H.:
 Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands

 Dept. of Endocrinol. and Metab. Dis., Leiden University Medical Center, Leiden, Netherlands

 Leiden University Medical Center, Dept. of Endocrinol./Metabol. Dis., P.O. Box 9600, 2300 RC Leiden, Netherlands
ISSN: 00121797
Editorial
AMER DIABETES ASSOC, 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 53 Número: 10
Páginas: 2529-2534
WOS Id: 000224116100002
ID de PubMed: 15448080
imagen Bronze